Moore Capital Management »

Black Diamond Therapeutics shares owned by Moore Capital Management

Quarter-by-quarter ownership of Black Diamond Therapeutics (BDTX) shares owned by Moore Capital Management from 13F filings

Historical chart of Moore Capital Management investment in Black Diamond Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Black Diamond Therapeutics held by Moore Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Black Diamond Therapeutics by Moore Capital Management

Quarter filed Position value Share count Share price at filing
2023-09-30 $65k 23k 2.87
2023-06-30 $253k 50k 5.05

More positions owned by Moore Capital Management

Spdr S&p 500 Etf Tr Tr Unit (SPY)
Microsoft Corporation Call Option (MSFT)
Ishares Tr Russell 2000 Etf (IWM)
Spdr S&p Midcap 400 Etf Tr Utser1 S&pdcrp (MDY)
Meta Platforms Cl A Call Option (META)
Invesco Qqq Tr Unit Ser 1 (QQQ)
NVIDIA Corporation Call Option (NVDA)
Ishares Tr 20 Yr Tr Bd Etf Call Option (TLT)
Bank of America Corporation (BAC)
Amazon (AMZN)
Freeport-mcmoran CL B Call Option (FCX)
Ally Financial (ALLY)
Aon Shs Cl A (AON)
Spotify Technology S A SHS (SPOT)
Netflix (NFLX)

View all positions for Moore Capital Management

Top funds holding Black Diamond Therapeutics

T. Rowe Price Investment Management
Vestal Point Capital
NEA Management Company
Vanguard Group
Tang Capital Management
Marshall Wace
Siren
BlackRock
Arrowstreet Capital, Limited Partnership
Millennium Management
UBS Group
AWM Investment Company
Renaissance Technologies
Geode Capital Management
Northern Trust

View all funds holding Black Diamond Therapeutics